DR. REDDY’S

Dr. Reddy is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India founded by Mr. Anji Reddy was incorporated on 24 February 1984. It is classified as a Non-govt company with an authorization share capital of Rs.1,200,000,000 and a paid-up capital of Rs.831,506,180. The company is a manufacturer and a marketer of a wide range of pharmaceuticals in India and overseas.

The shareholding pattern consists of: Promoters (26.74%), FII (29.03%), Public (28.99%), DII (14.90%) and Others (0.35%). The company at present is trading on BSE and NSE, and as well as on NYSE.

Dr. Reddy has been in highlights for past few months for their COVID portfolio-

• They have launched Redyx (Remdesivir) in India and other 127 countries for Covid-19 treatment in September,2020.
• They also launched Avigan (with Fujifilm Holding Crop) for restricted emergency use to treat mild to moderate COVID-19, after a result showing 2100 patients received the drug to use in Japan.
• On May 12,2021, the Drug Controller General of India (DGCI) gave the emergency use approval to 2-deoxy-D-glucose (2-DG), an anti-COVID drug developed by INMAS< a DRDO lab, with collaboration of Dr.Reddy’s Laboratories.
• Russia also signed an agreement of sending Sputnik V vaccines for treating Covid-19 to India. The first consignment of imported dose of the vaccine was received regulatory clearance on May 13,2021 by Central Drugs Laboratory.
• Recently, the company has also announced the launch of Ertapenem for injection in the U.S market.

For the quarter ending March 31,2021, –

• The company has recorded a surge in its consolidated revenue by 7.17% from the same quarter last year which was Rs.4448.9 Cr. against Rs.4768.2 Cr. this quarter.
• Their PAT slipped by 28.65% YoY to Rs.557 Cr. From Rs.781 Cr. in the same quarter last year.
• The company has shown an EPS value of 33.61 crore for Q4 against Rs.47.12 Cr. last year this time.
• Their yearly revenue showed a raise of 8.73% and stands at Rs.19047.5 Cr. against Rs. 17517 Cr. last year.
• The company’s sales for Q4 FY19 was a mix between: North America (having the major share as 37%), Europe, India, PSAI, Emerging markets and proprietary products and others.

Commenting on the company’s Q4 results, they have shown a significant turnaround in the financial performance and steady progress on the quality front as well. The CEO and Co-chairman, G.V. Prasad has said that they will focus on more profitable growth and continue the emphasis on operational excellence and innovation. The board of the company has also announced a dividend of 500% of its share’s face value at Rs.25 per share.